Yüklüyor......
Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries
BACKGROUND: As alternatives to warfarin, 2 novel oral anticoagulants (NOACs), dabigatran and rivaroxaban, were approved in 2010 and 2011 to prevent stroke and other thromboembolic events in patients with atrial fibrillation. It is unclear how patient characteristics are associated with the initiatio...
Kaydedildi:
| Yayımlandı: | J Manag Care Spec Pharm |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Academy of Managed Care Pharmacy
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5051348/ https://ncbi.nlm.nih.gov/pubmed/27003558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2016.22.3.281 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|